Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $299 thousand, versus $247 thousand reported last year.

Cyclacel reported Q413 loss of $0.21 per share.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.